Company intelligence / Profile preview

Novamab Biopharmaceuticals

Shanghai, Shanghai, Chinaen.novamab.com ↗

Ownership: Private
Employees: ~60
Development stage: Other

Overview

Novamab is developing the world's first inhaled VHH antibody drugs for asthma and COPD (LQ036, LQ043H). Phase I studies in China and Australia showed excellent safety and biomarker efficacy for LQ036, with Phase II ongoing. LQ043H has completed Phase Ia showing strong safety and tolerance. Additional pipeline assets are progressing in autoimmune, inflammatory, and neoplastic diseases.[1][4][5][6][9][10]

Therapeutic areas: ImmunologyOphthalmologyGastroenterologyPulmonologyOncology
Modalities: NanobodyVHH antibodyMonoclonal antibodyBispecific monoclonal antibodyRadiolabeled antibody
Industry: Biotech

Drug pipeline

10 assets

LQ036

9 more assets in the full pipeline.

Partnerships

Strategic partnerships with multiple domestic and foreign enterprises (specific names not disclosed)[2]

Beyond the preview

Go deeper on Novamab Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novamab Biopharmaceuticals.